METTL3 and cancer: Further, STM2475, the first-in-class non-nucleoside Mettl3 inhibitor, has demonstrated its efficacy in the treatment of malignant tumors in vitro, which is an exciting achievement in the field of Mettl3 research (Yankova et al., 2021).